Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19

TY - JOUR

T1 - Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker

T2 - Implications for COVID-19

AU - Wysocki, Jan

AU - Lores, Enrique

AU - Ye, Minghao

AU - Soler, Maria Jose

AU - Batlle, Daniel

N1 - Funding Information: This work was supported by the Joseph and Bessie Feinberg Foundation (Dr. Daniel Batlle). We thank Dr. Hong D. Xiao (Providence Portland Medical Center, Portland, OR) and Dr. Kenneth E. Bernstein (Cedars Sinai, Los Angeles, CA) for generously providing kidneys from ACE deficiency models. Dr. Daniel Batlle reports nonfinancial support from Angiotensin Therapeutics Inc., outside the submitted work. Dr. Maria Jose Soler reports personal fees from AstraZeneca, nonfinancial support from Boehringer In-gelheim, nonfinancial support from Eli Lilly, personal fees and nonfinancial support from Esteve, personal fees from FMC, personal fees from Janssen, personal fees from Mundi-pharma, and personal fees from NovoNordisk, outside the submitted work. Funding Information: D. Batlle was funded by National Institute of Diabetes and Digestive Kidney Diseases grant RO1DK104785.

PY - 2020/9

Y1 - 2020/9

UR - http://www.scopus.com/inward/record.url?scp=85090174789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090174789&partnerID=8YFLogxK

U2 - 10.1681/ASN.2020050667

DO - 10.1681/ASN.2020050667

M3 - Letter

C2 - 32669323

AN - SCOPUS:85090174789

VL - 31

SP - 1941

EP - 1943

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 9

ER -